Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK I1171N||Advanced Solid Tumor||sensitive||ALK Inhibitor||Brigatinib||Preclinical - Cell culture||Actionable||In a preclinical study, a transformed cell line expressing ALK I1171N was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).||27049722|
|ALK I1171N||Advanced Solid Tumor||decreased response||ALK Inhibitor||TPX-0131||Preclinical - Biochemical||Actionable||In a preclinical study, ALK I1171N demonstrated reduced sensitivity to TPX-0131 in an in vitro kinase assay (PMID: 34158340).||34158340|
|ALK I1171N||Advanced Solid Tumor||sensitive||ALK Inhibitor||Repotrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, Repotrectinib (TPX-0005) decreased Alk phosphorylation and neurite outgrowth in cells expressing ALK I1171N in culture (PMID: 31852910).||31852910|